Director at IDEAYA Biosciences (IDYA) receives 20,000-share stock option grant

Rhea-AI Filing Summary

IDEAYA Biosciences director Catherine J. Mackey received a stock option grant covering 20,000 shares of Common Stock. The option has an exercise price of $30.57 per share and expires on June 16, 2036. All 20,000 option shares vest on the earlier of the first anniversary of the grant date or immediately before the next Annual Meeting, if she continues serving on the Board.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider MACKEY CATHERINE J

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	20,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 20,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 20,000 shares Exercise price: $30.57 per share Expiration date: June 16, 2036 +1 more

4 metrics

Option grant size 20,000 shares Stock option covering Common Stock

Exercise price $30.57 per share Stock option strike price

Expiration date June 16, 2036 Option term end

Post-transaction derivative holdings 20,000 options Total stock options held directly after grant

Key Terms

Stock Option (right to buy), exercise price, expiration date, Annual Meeting, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 30.5700"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-16T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Annual Meeting financial

"immediately prior to the Annual Meeting following the date of grant"

A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.

vesting financial

"100% of the shares subject to the option shall vest in full"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MACKEY CATHERINE J

(Last) (First) (Middle)

C/O IDEAYA BIOSCIENCES, INC.

5000 SHORELINE COURT, SUITE 300

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IDEAYA Biosciences, Inc. [ IDYA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$30.57	06/16/2026		A		20,000		(1)	06/16/2036	Common Stock	20,000	$0	20,000	D

Explanation of Responses:

1. 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date.

	/s/ Andres Ruiz Briseno, as Attorney-in-Fact for Catherine J. Mackey	06/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did IDEAYA Biosciences (IDYA) report for Catherine J. Mackey?

IDEAYA Biosciences reported that director Catherine J. Mackey received a stock option grant for 20,000 shares of Common Stock at a $30.57 exercise price. This award represents equity-based compensation tied to her continued Board service.

What are the terms of Catherine J. Mackey’s new stock options at IDEAYA Biosciences (IDYA)?

The stock options cover 20,000 underlying shares of Common Stock with a $30.57 exercise price and expire on June 16, 2036. These terms define how long she can exercise the options and at what price.

When do Catherine J. Mackey’s IDEAYA (IDYA) stock options vest?

All 20,000 option shares vest 100% on the earlier of the first anniversary of the June 16, 2036 grant date or immediately before the next Annual Meeting, assuming she continues serving on the Board through the vesting date.

Is Catherine J. Mackey’s IDEAYA (IDYA) option grant a market purchase or compensation award?

The filing classifies the 20,000-share stock option as a grant or award acquisition rather than an open-market purchase. It reflects compensation for Board service, not a discretionary stock purchase in the market.

How many IDEAYA (IDYA) derivative securities does Catherine J. Mackey hold after this grant?

Following this transaction, Catherine J. Mackey holds 20,000 stock options directly according to the filing. These options each relate to one share of IDEAYA Biosciences Common Stock upon exercise at the set $30.57 price.